Spine Biopharma’s $13 Million Series B Equity Financing

McDermott Will & Emery represented Spine Biopharma in the transaction.Spine Biopharma, Inc, a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of pain…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here